Design, Characterisation and Evaluation of Sustained Release Formulation of Remogliflozin Etabonate
DOI:
https://doi.org/10.22270/ajprd.v12i6.1431Abstract
Now-a-days Type 2 diabetes mellitus is a very crucial common disease and emerging condition that glucose level of Human body cannot be controlled. In case of Type-2 diabetes mellitus, pancreas does not produce enough insulin. In such a condition, we have to thing for a medicament for treating the disease; Remogliflozin Etabonate is such type of drug that efficacious and safe agent that we can administer in our body. The Half-Life of the drug is 120 minutes.This research has taken into consideration on improving the release pattern of the drug by sustaining its action at maximum level of time, using the different ratios of Polymer and discusses the individual studies performed during its development for design, characterization and evaluation of analytical and formulative profile, as well as in-vitro Characterization. In that case, this research work is hopefully very much useful for further proceeding and for large scale aspect in industrial point of view.
Downloads
References
Waller DG, Sampson AP, Renwick AG, Hiller K. Medical pharmacology and therapeutics; 4th edn, 457.
Tripathi, KD. Essential of medical pharmacology; 7th edn; Jaypee brothers medical publisher PVT. LTD. New Delhi, 2013; 258.
Attimarad, M.; Venugopala, K.; Sreeharsha, N.; Chohan, M.; Shafi, S.; Nair, A.; Pottathil, S. A rapid HPLC method for the concurrent determination of several antihypertensive drugs from binary and ternary formulations. Separations 2021, 8, 86. [CrossRef]
Development and Validation of Novel RP-HPLC Method for the Simultaneous Determination of Remogliflozin and Vildagliptin in Bulk and in synthetic Mixture Drashti A. Mandale1* , Chainesh Shah2 and Rakesh Jatt3; Journal of Pharmaceutical Research International 33(40B): 338-349, 2021; Article no.JPRI.71901 ISSN: 2456-9119 (Past name: British Journal of Pharmaceutical Research, Past ISSN: 2231-2919, NLM ID: 101631759)
Fujimori Y, Katsuno Y, Nakashima I (2008) Remogliflozin etabonate, in a novel category of selective low affinity sodium glucose cotransporter inhibitors, exhibit antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 327(1):268–276. https://doi.org/10.1124/jpet.108.140210 [TLC]
Tayade AB, Patil AS, Shirkhedkar AA (2019) Development and validation of zero order UV-spectrophotometric method by area under curve technique and high performance thin layer chromatography for the estimation of remogliflozin etabonate in bulk and in house tablets. Inventi Rapid: Pharm Anal Qual Assurance 3:1–5 [TLC]
D. J. Magliano, J. W. Sacre, J. L. Harding, E. W. Gregg, P. Z. Zimmet, and J. E. Shaw, Nature Reviews Endocrinology, 16(6), 321(2020), DOI:10.1038/s41574-020-0334-z [ANALYTICAL]
M. K. Moon, K. Y. Hur, S. H. Ko, S. O. Park, B. W. Lee, J. H. Kim, S. Y. Rhee, H. J. Kim, K. M. Choi, and N. H. Kim, Korean Journal of Internal Medicine, 32(6), 974(2017), DOI:10.3904/kjim.2017.354[ANALYTICAL]
inman B, Wanner C, Lachin JM, et al. Remogliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–2128.
Joshi S, Gudi G, Menon VC, et al. An openlabel, single-period, two-stage, single oral dose pharmacokinetic study of RemogliflozinEtabonate tablet 100 and 250 mg in healthy asian indian male subjects under fasting and fed conditions. Clin Pharmacokinet. 2020;59(3):349–357 [KINETIC]
Shanmuga SD, Vamshikrishna D, Ragapallavi C, “A simple method development and validation for the simultaneous estimation of remogliflozin etaboante and metformin hcl by RP-HPLC method” Ind. Ame. J. Pharm. Res., 2013; 3(10): 8169-8177. [ANALYTICAL]
Sidhhartha B, Babu IS, Gupta CR, Parthiban C, “Analytical method development and validation for simultaneous estimation of remogliflozin etaboante and metformin hcl in bulk & pharmaceutical dosage form by RP-HPLC method” Asi. J. Pharm. and Cloi. Res., 2014; 7(2): 156-160. [ANALYTICAL]
Saxena V, Zaheer Z, Farooqui M, “Stability Indicating RP-HPLC Method for the Determination of remogliflozin etaboante and metformin hcl in Pharmaceutical formulation” Ind. J. of Chem. Tech. Res., 2006; 13: 242-246. [ANALYTICAL]
FDA, "Guidance for Industry; Analytical Procedures and Methods Validation (Draft guidance), Food & Drug Administration,” Rockville, US Department of Health and Human Services, 2000.
Weiner ID, Mitch WE, Sands JM. Urea and Ammonia Metabolism and the Control of Renal Nitrogen Excretion. Clinical Journal of the American Society of Nephrology. August 2015, 10 (8): 1444–58. [RE-DOSAGE]
Nieto-Martínez R, González-Rivas JP, Medina-Inojosa JR, Florez H. Are Eating Disorders Risk Factors for Type 2 Diabetes? A Systematic Review and Meta-analysis. Current Diabetes Reports (Systematic review and meta-analysis). 22 November 2017, 17 (12): 138. [RE-DOSAGE]
*Kokkeragadda Akhila, Dr. Srinivasa Rao N, “New Validated Method For The Estimation Of Remogliflozin In Pharmaceutical Dosage Form Using RP-HPLC”, JETIR January 2022, Volume 9, Issue 1, ISSN:2349-5162. [RE-DOSAGE]
J. W. Polli, J. E. Humphreys, K. A. Harmon, L. O. Webster, M. J. Reese and C. C. MacLauchlin (2012) Assessment of Remogliflozin etabonate, a sodium dependent glucose co-transporter-2 inhibitor, as a perpetrator of clinical drug interactions: A study on Drug transporters and metabolic enzyme, J. Diabetes Metab. 3(5), 1-8
J. F. Sigafoos, G. D. Bowers, S. Castellino, A. G. Culp, D. S. Wagner, M. J. Reese, J. E. Humphreys, E. K. Hussey, R. L. O’Connor Semmes, A. Kapur, W.Tao, R.L. Dobbins and J.W. Polli (2012) Assessment of the drug interaction risk for remogliflozin etabonate, a sodium-dependent glucose cotransporter-2 inhibitor: evidence from in vitro, human mass balance, and ketoconazole interaction studies, Drug Metab. Dispos. 40, 2090–2101
A. B. Tayade, A. S. Patil and A. A. Shirkhedkar (2019) Development and validation of zero order spectrophotometric method by area under curve technique and high performance thin layer chromatography for the estimation of Remogliflozin etabonate in bulk and in-house tablets, Invent. Rapid: Pharm. Anal. Qual. Assur. 3, 1-5.
Li, X.; Huang, X.; Bai, C.; Qin, D.; Cao, S.; Mei, Q.; Ye, Y.; Wu, J. Efficacy and safety of teneligliptin in patients with type 2 diabetes mellitus: A systematic review and meta-analysis of randomized controlled trials. Front. Pharmacol. 2018, 9, 449. [CrossRef] [PubMed] [SUSTAINED]
Attimarad, M.; Venugopala, K.; Sreeharsha, N.; Chohan, M.; Shafi, S.; Nair, A.; Pottathil, S. A rapid HPLC method for the concurrent determination of several antihypertensive drugs from binary and ternary formulations. Separations 2021, 8, 86.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Aveek Datta, Dr. Subhasis Maity, Dr. Miltu Kr. Ghosh, Dr. Kuntal Hazra
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
AUTHORS WHO PUBLISH WITH THIS JOURNAL AGREE TO THE FOLLOWING TERMS:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 4.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
.